Small Cell Lung Cancer
A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer
The purpose of this study is to evaluate the safety and efficacy of prexasertib when given to participants with extensive stage disease small cell lung cancer (ED-SCLC). The study will evaluate how the body processes the drug and how the drug affects the body. The study will also evaluate the association between tumor response and the participant's perceived quality of life.
The results of this study are not yet available.
Your participation could last up to 1 year after the last patient enrolls in the study and if you are still receiving benefit, you may continue to receive Prexasertib through a continued access program.
Here you can find out a bit more about the requirements for volunteers who took part in this study
- Participant must have extensive stage disease small cell lung cancer (ED-SCLC) and have received a prior platinum-based regimen
- Participant must not have received more than 2 prior therapies for ED-SCLC (including immunotherapy, targeted therapies, or chemotherapy)
- Participant must not have previously completed or withdrawn from this study or any other study investigating prexasertib or a checkpoint kinase I (CHK1) inhibitor